ESMO 2017 | Rituximab and its biosimilars: consistencies and advantages
Rituxumab, an anti-CD20 monoclonal antibody, is often used to treat various forms of cancer. Wojciech Jurczak, MD, PhD, from the Jagiellonian University, Kopernika, Poland explains how the nature of this agent affects its consistency, and discusses an advantage in using biosimilars which mimic this original molecule. This interview was recorded at the 2017 European Society for Medical Oncology (ESMO) conference held in Madrid, Spain.
Get great new content delivered to your inboxSign up